Bristol-Myers Squibb has discontinued the manufacture and sales of its antidepressant Serzone, which has been linked to 55 cases of liver disease, including 20 deaths. The official halt date will be June 14.

The company said the drug had poor sales. Serzone is one of 17 drugs the New York-based company is discontinuing.

In March, U.S. consumer group Public Citizen sued the Food and Drug Administration in an attempt to force a ban on Serzone.  Dr. Sidney Wolfe, head of Public Citizen’s Health Research Group, said the company should recall the Serzone that’s already available, as well as its generic versions. The company said it stands by its contention that the drug is safe.